This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John F. Kessler, MD; Stephen E. Jones, MD; Norman Levine, MD; Peter J. Lynch, MD; Ann Rohman Booth, RN; Frank L. Meyskens, Jr, MD

Arch Dermatol. 1987;123(2):201-204.

Abstract
• Retinoids, including isotretinoin, have demonstrated antiproliferative and antineoplastic activity in laboratory and clinical trials. In a phase II trial, 25 patients with extensive mycosis fungoides were evaluated for response to isotretinoin. There was a 44% (11 patients) objective clinical response rate with three clinical complete responses without concomitant evidence of pathologic clearing of the disease. An additional 24% (six patients) showed a minor degree of clinical improvement. The median time to response was two months (range, 0.5 to eight months) and the median response duration was eight months or longer (range, one to 25 months). Chronic toxic reactions consisted primarily of drying of the skin and mucous membranes and resulted in dose reduction in the majority of patients. It is concluded that isotretinoin produces significant clinical benefit to some patients with mycosis fungoides.

(Arch Dermatol 1987;123:201-204)

Author Affiliations
From the Sections of Hematology/Oncology (Drs Kessler, Jones, and Meyskens and Ms Booth) and Dermatology (Drs Levine and Lynch), Department of Internal Medicine, and Arizona Cancer Center, University of Arizona, Tucson. Dr Jones is now with the Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas.

Footnotes
Accepted for publication July 3, 1986.

Read before the 21st annual meeting of the American Society of Clinical Oncology, Houston, May 20, 1985.

Reprint requests to Arizona Cancer Center, University of Arizona, Tucson, AZ 85724 (Dr Meyskens).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the Journey: The Long and Winding Road of Chemoprevention Agent Development.
Meyskens
Cancer Epidemiol. Biomarkers Prev. 2006;15:2038-2041.
FULL TEXT  

Induction of Apoptosis by Bexarotene in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action
Zhang et al.
Clin. Cancer Res. 2002;8:1234-1240.
ABSTRACT | FULL TEXT  

Lymphoma of the Skin
Connors et al.
ASH Education Book 2002;2002:263-282.
ABSTRACT | FULL TEXT  

Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results
Duvic et al.
JCO 2001;19:2456-2471.
ABSTRACT | FULL TEXT  

Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma
Duvic et al.
Arch Dermatol 2001;137:581-593.
ABSTRACT | FULL TEXT  

Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts
Siegel et al.
JCO 2000;18:2908-2925.
ABSTRACT | FULL TEXT  

New Therapies for Cutaneous T-Cell Lymphoma
Heald and Edelson
Arch Dermatol 1987;123:189-191.
ABSTRACT